细胞表面标记检测的全球市场：市场规模和占有率分析（依产品和应用）、产业收入估算和需求预测（截至2030年）

2023年全球细胞表面标记检测市场规模估计为55.055亿美元，2030年将达到94.274亿美元，推动预测期内成长率为8.1%。该行业的推动因素包括对精准医疗的需求不断增长、体外诊断接受度的提高以及提高吞吐量和自动化率的技术进步。

流式细胞仪设备引领市场

流式细胞仪设备占比最大，2023年将达35%。这主要是因为该方法可以测量同一样本中的大量参数，并且可以在几秒钟内收集数百万个细胞的数据。

药物发现和研究领域成长最快的应用

到2030年，药物发现和研究领域将以8.4%的速度成为业界成长最快的领域。其主要原因是慢性病的增加以及随之而来的医疗费用的急剧增加。

据一份报告称，2000年，美国有超过1.2亿人患有至少一种慢性病。直到2030年，这个数字每年都会增加1%以上。

因此，2000年至2030年间，北美慢性病患者人数将增加约40%，即约5,000万人。

北美地区处于领先地位

北美是该市场的区域领导者，到 2023 年将占 55% 的占有率。这是由于技术进步、老年人口不断增长以及慢性病盛行率不断上升。

亚太地区将成长最快

预计到本十年末，亚太地区将经历最快的成长。这主要是由于老年人数量的增加以及药物发现和研究的最新进展，特别是在基因治疗方面。该行业的发展也受到心血管疾病、糖尿病和癌症患者数量不断增加的推动。

在印度，受癌症影响的人数预计将从 2021 年的约 2,700 万人增加到 2025 年的约 3,000 万人。

本报告分析了全球细胞表面标记检测市场，提供了市场的基本结构、最新情况、主要促进和抑制因素以及全球、依地区和主要国家的市场规模前景（价值基础，2017年） -2030），依产品和应用划分的详细趋势、当前市场竞争状况以及主要公司简介。

目录

第一章 调查范围

第二章 研究方法

第3章执行摘要

第四章 市场指标

第五章 产业展望

• 市场动态
  • 趋势
  • 促进因素
  • 抑制因素/课题
  • 促进/抑制因素影响分析
• 新型冠状病毒感染（COVID-19）的影响
• 波特五力分析

第六章 世界市场

• 概述
• 市场收入：依产品分类（2017-2030）
• 市场收入：依应用分类（2017-2030）
• 市场收入：依地区（2017-2030）

第七章 北美市场

• 概述
• 市场收入：依产品分类（2017-2030）
• 市场收入：依应用分类（2017-2030）
• 市场收入：依国家分类（2017-2030）

第八章欧洲市场

第九章亚太市场

第十章 拉丁美洲市场

第十一章 中东和非洲（MEA）市场

第十二章 美国市场

• 概述
• 市场收入：依产品分类（2017-2030）
• 市场收入：依应用分类（2017-2030）

第十三章 加拿大市场

第十四章 德国市场

第十五章 法国市场

第十六章 英国市场

第十七章 义大利市场

第十八章 西班牙市场

第十九章 日本市场

第20章 中国市场

第21章 印度市场

第22章澳洲市场

第23章 韩国市场

第24章 巴西市场

第25章 墨西哥市场

第26章 沙乌地阿拉伯市场

第27章南非市场

第28章 阿拉伯联合大公国（UAE）市场

第29章竞争格局

• 市场参与者及其提供的产品/服务的列表
• 主要企业竞争基准
• 主要公司的产品基准
• 近期策略发展状况

第三十章 公司简介

• Abbott Laboratories
• Becton, Dickinson and Company
• Nihon Kohden Corporation
• Thermo Fisher Scientific Inc.
• Sysmex Corporation
• Janssen Diagnostics Inc.
• Grifols SA
• Siemens Healthcare
• BioRad Laboratories Inc.
• F. Hoffmann-La Roche Ltd.

第31章附录

The size of the cell surface marker detection market was USD 5,505.5 million in 2023, and it will touch USD 9,427.4 million by 2030, propelling at a rate of 8.1% during the projection period. The industry is powered by the increase in the requirement for precision medicine, the increase in the acceptance of in vitro diagnostics, and tech advancements that enhance throughput and the automation rate.

Drivers of the Industry

Cell surface markers help in recognizing high-risk patients precisely, enhancing the accuracy of the diagnosis, progressing follow-up policies for people, estimating susceptibility to targeted therapy or immunotherapy, and predicting prognostic outcomes.

Precision medicine is used in the treatment of many subspecialties, mostly in cancer and inherited diseases, for both diagnosis and treatment, using next-gen sequencing.

Precision medicine reduces the cost of care and advances the overall health of people through the use of pharmacogenomics, which uses patient data to create effective and safe plans for the medication of patients.

Precision medicine is a cutting-edge method of altering the approaches to disease prevention and treatment.

It will allow doctors and researchers to predict more precisely the most appropriate treatment with information on the molecular and genetic makeup of the patient, environment, and lifestyle.

Flow Cytometry Instruments Led the Market

The flow cytometry instruments had the largest share, of 35%, in 2023. This is principally because this method can measure numerous parameters in the same sample and collect data from millions of cells within seconds.

Moreover, with this method, any non-uniformity in a uniform cell populace is detected, and it also eliminates all the dead cells or debris when the final data is provided.

Drug Discovery and Research is the Fastest Growing Application

The drug discovery and research category will grow the fastest in the industry, with a rate of 8.4%, by 2030. This is mostly because of the increasing occurrence of chronic ailments and the resulting surge in healthcare spending.

As per a report, in 2000, in the U.S., people with over one chronic condition were over 120 million. This number will increase by over 1% every year till 2030.

Hence, between 2000 and 2030, the number of people in North America with chronic conditions will surge by about 40% or around 50 million individuals.

North America is the Regional Leader

North America was the regional leader of the market, with a 55% share, in 2023, because of the growing count of tech progressions, surging elderly population, and growing incidence of chronic diseases.

In the U.S., there is an increase in the count of citizens aged 65 and more. This share of the elderly people in the total populace will rise to about 24% by 2060 from 15% in 2016.

The aging population is more susceptible to chronic ailments, for example, cardiac conditions, gastrointestinal issues, and cancer. Moreover, the U.S. is the 5th globally for age-standardized rates for all cancers.

APAC To Experience Fastest Growth

APAC will have the fastest growth by the end of this decade. This is mostly due to the increasing number of elderly people and recent advances in drug discovery and research procedures, particularly in gene therapy. The rising populace of patients with CVDs, diabetes, and cancer is also powering the industry.

In India, the number of people suffering from cancer will increase to about 30 million in 2025 from approximately 27 million in 2021.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by product
  • 1.4.2. Market size breakdown, by application
  • 1.4.3. Market size breakdown, by region
  • 1.4.4. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Revenue, by Product (2017-2030)
• 6.3. Market Revenue, by Application (2017-2030)
• 6.4. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Revenue, by Product (2017-2030)
• 7.3. Market Revenue, by Application (2017-2030)
• 7.4. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Revenue, by Product (2017-2030)
• 8.3. Market Revenue, by Application (2017-2030)
• 8.4. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Revenue, by Product (2017-2030)
• 9.3. Market Revenue, by Application (2017-2030)
• 9.4. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Revenue, by Product (2017-2030)
• 10.3. Market Revenue, by Application (2017-2030)
• 10.4. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Revenue, by Product (2017-2030)
• 11.3. Market Revenue, by Application (2017-2030)
• 11.4. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Revenue, by Product (2017-2030)
• 12.3. Market Revenue, by Application (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Revenue, by Product (2017-2030)
• 13.3. Market Revenue, by Application (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Revenue, by Product (2017-2030)
• 14.3. Market Revenue, by Application (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Revenue, by Product (2017-2030)
• 15.3. Market Revenue, by Application (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Revenue, by Product (2017-2030)
• 16.3. Market Revenue, by Application (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Revenue, by Product (2017-2030)
• 17.3. Market Revenue, by Application (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Revenue, by Product (2017-2030)
• 18.3. Market Revenue, by Application (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Revenue, by Product (2017-2030)
• 19.3. Market Revenue, by Application (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Revenue, by Product (2017-2030)
• 20.3. Market Revenue, by Application (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Revenue, by Product (2017-2030)
• 21.3. Market Revenue, by Application (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Revenue, by Product (2017-2030)
• 22.3. Market Revenue, by Application (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Revenue, by Product (2017-2030)
• 23.3. Market Revenue, by Application (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Revenue, by Product (2017-2030)
• 24.3. Market Revenue, by Application (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Revenue, by Product (2017-2030)
• 25.3. Market Revenue, by Application (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Revenue, by Product (2017-2030)
• 26.3. Market Revenue, by Application (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Revenue, by Product (2017-2030)
• 27.3. Market Revenue, by Application (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Revenue, by Product (2017-2030)
• 28.3. Market Revenue, by Application (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. Abbott Laboratories
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. Becton, Dickinson and Company
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
  • 30.2.3. Key financial summary
• 30.3. Nihon Kohden Corporation
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. Thermo Fisher Scientific Inc.
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
  • 30.4.3. Key financial summary
• 30.5. Sysmex Corporation
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary
• 30.6. Janssen Diagnostics Inc.
  • 30.6.1. Business overview
  • 30.6.2. Product and service offerings
  • 30.6.3. Key financial summary
• 30.7. Grifols SA
  • 30.7.1. Business overview
  • 30.7.2. Product and service offerings
  • 30.7.3. Key financial summary
• 30.8. Siemens Healthcare
  • 30.8.1. Business overview
  • 30.8.2. Product and service offerings
  • 30.8.3. Key financial summary
• 30.9. BioRad Laboratories Inc.
  • 30.9.1. Business overview
  • 30.9.2. Product and service offerings
  • 30.9.3. Key financial summary
• 30.10. F. Hoffmann-La Roche Ltd.
  • 30.10.1. Business overview
  • 30.10.2. Product and service offerings
  • 30.10.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports